Knockdown of β5 in breast cancer cells was accompanied by decreased FAK and ERK signaling (Bianchi-Smiraglia et al., 2013); while we also observed decreased levels of phosphorylated FAK, mainly in β5-deficient HT29 and U251MG, we did not detect obvious changes in ERK activity. This evidence concerns the gene PTK2 and breast cancer.